Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is a global leader in innovative and comprehensive laboratory services, headquartered in Burlington, NC. With over 35 years of experience, Labcorp performs more than one million tests on approximately 400,000 samples daily, serving more than 220,000 clients worldwide, including physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies.
Labcorp operates a sophisticated laboratory network, consisting of roughly 2,000 patient-service centers. The company offers a broad range of 5,000 clinical lab tests ranging from routine blood and urine screens to complex oncology and genomic testing. Additionally, Labcorp is known for its scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology.
Recently, Labcorp has been active in expanding its operations and capabilities. For instance, it was selected as the winning bidder to acquire assets of Invitae, a leading medical genetics company, for $239 million. This acquisition is expected to bolster Labcorp's genetic specialty testing capabilities, particularly in oncology and rare diseases.
Labcorp continues to innovate, having launched the first trimester preeclampsia screening test in the U.S., which helps determine the risk of developing preeclampsia before 34 weeks of pregnancy. The company's commitment to advancing maternal and fetal health is also evident in its comprehensive preeclampsia screening offerings across all trimesters of pregnancy.
Moreover, Labcorp announced enhancements to its precision oncology portfolio, including the launch of Labcorp Tissue Complete and OmniSeq INSIGHT for ctDNA. These offerings are designed to support biopharmaceutical companies in advancing cancer research and patient care globally.
Financially, Labcorp reported first-quarter revenue of $3.18 billion in 2024, a 4.6% increase from the previous year. The company's adjusted operating income for the quarter was $452.8 million, or 14.3% of revenue. Labcorp's ongoing financial stability is demonstrated by its strong cash balance and total debt management.
Labcorp has a significant impact in the healthcare industry, supporting 84% of the new drugs and therapeutic products approved by the FDA in 2023. With over 67,000 employees serving clients in approximately 100 countries, Labcorp is dedicated to providing insights and advancing science to improve health and lives globally. To learn more about Labcorp, visit www.labcorp.com.
Labcorp (NYSE: LH) is set to announce its first quarter 2021 financial results before market opening on April 29, 2021. The company will host a conference call at 9:00 a.m. ET to discuss the results, which will be available on the Labcorp Investor Relations website. An audio replay will be accessible until May 13, 2021. Labcorp, a prominent global life sciences firm, reported $14 billion in revenue for FY2020, emphasizing its capability in diagnostics and drug development. The release includes forward-looking statements about COVID-19's impact on business operations.
Labcorp (NYSE: LH) announced the appointment of Kathryn Wengel, previously Executive Vice President at Johnson & Johnson, to its Board of Directors, expanding the board from 9 to 10 members. Wengel brings over 30 years of experience in managing healthcare organizations and global supply chains, which Labcorp anticipates will enhance its operational capabilities. Labcorp's Chairman and CEO, Adam Schechter, emphasized the importance of diverse perspectives in the boardroom, aiming to strengthen the company’s mission in healthcare.
Labcorp (NYSE: LH) has announced its ongoing efforts to enhance its business strategy and capital allocation to unlock shareholder value. The company is making significant advancements in diagnostics and drug development, particularly in areas like oncology and COVID-19. To facilitate this review, Labcorp's Board of Directors has engaged Goldman Sachs & Co. LLC as a financial advisor. The company emphasizes its commitment to improving patient health and its role in combating COVID-19.
Labcorp (NYSE: LH) announces that Dr. Marcia Eisenberg, chief scientific officer, has been honored as a 2021 Luminary by the Healthcare Businesswomen’s Association (HBA). Dr. Eisenberg's recognition celebrates over 30 years of contributions to healthcare innovation and her support for women in STEM. She has played a pivotal role in the commercialization of PCR testing and COVID-19 diagnostics. The honor will be conferred during the virtual Woman of the Year event on May 6. Labcorp reported $14.0 billion in revenue for FY2020.
Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum on March 24 at 2:00 p.m. ET. A live webcast of the presentation will be available on the company's website and archived for later viewing.
Labcorp is a global life sciences leader, providing essential diagnostic and drug development services. The company reported revenue of $14 billion in FY2020 and serves clients in over 100 countries.
Labcorp (NYSE: LH) and PathAI have expanded their strategic partnership focusing on AI-powered pathology. This collaboration will enable seamless deployment of PathAI algorithms in clinical trials managed by Labcorp. Key objectives include enhancing patient stratification and developing companion diagnostic devices using robust AI-driven analytics. Labcorp aims to leverage this collaboration to advance drug development and improve patient outcomes, reflecting significant developments in digital pathology.
Walgreens has partnered with Labcorp to sell the Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter at 6,000 stores nationwide. Starting spring 2021, this will be Walgreens' first in-store testing option, enhancing access in underserved areas. Walgreens aims to increase its on-site testing capacity to over 5,000 locations by April 1. The kits allow customers to self-administer tests and send samples to Labcorp for processing. Test results will be available online, with follow-up by healthcare professionals for positive results.
Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25 at 1:30 p.m. ET. A live webcast of the event will be available on the company's website and archived for later replay.
As a leading global life sciences company, Labcorp reported $14 billion in revenue for FY2020 and employs over 75,000 people serving clients in more than 100 countries, providing vital insights and innovations to improve health.
Labcorp (NYSE: LH) has launched a new laboratory-based antigen test to help determine active COVID-19 infections. Developed by DiaSorin, this test requires a doctor's order and is conducted using a nasal or nasopharyngeal swab. Results are typically available within 24-48 hours. Labcorp emphasizes that while PCR tests remain the gold standard for COVID-19 diagnosis, antigen tests are an important tool for assessing infection status. The test has been made available in the U.S. following FDA notification on October 26, 2020.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
What does Labcorp Holdings Inc. specialize in?
How extensive is Labcorp's network?
What recent acquisitions has Labcorp made?
What new test has Labcorp launched for pregnant individuals?
How did Labcorp perform financially in the first quarter of 2024?
How many employees does Labcorp have?
What is Labcorp's involvement in the development of new drugs?
What is Labcorp's role in cancer research?
What is unique about Labcorp's preeclampsia screening test?
Where can I learn more about Labcorp and its services?
